Compass Therapeutics
CMPX
Market cap $286M

1.86 USD

+0.02

1.09%

At close Apr 30, 4:00 PM EDT

After hours

1.96

+0.10

5.38%

1 day

1.09%

5 days

-10.58%

1 month

-2.11%

3 months

-38.41%

6 months

8.77%

Year to date

32.86%

1 year

29.17%

5 years

-53.27%

10 years

-53.27%

About: Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Employees: 35

Healthcare Biotechnology

Funds holding %

of 7,425 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

217% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 6

118% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 17

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

15% more funds holding

Funds holding: 79 [Q3] → 91 (+12) [Q4]

6.66% more ownership

Funds ownership: 67.0% [Q3] → 73.67% (+6.66%) [Q4]

13% less capital invested

Capital invested by funds: $170M [Q3] → $147M (-$22.6M) [Q4]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

223%

upside

Avg. target

$16.40

782%

upside

High target

$32

1,620%

upside

5 analyst ratings

5 positive

100%

0 neutral

0 negative

D. Boral Capital Jason Kolbert 28% 1-year accuracy 107 / 376 met price target	1,620%upside $32	Buy Maintained	28 Apr 2025
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 89 / 416 met price target	1,190%upside $24	Buy Reiterated	21 Apr 2025
Leerink Partners Andrew Berens 20% 1-year accuracy 1 / 5 met price target	223%upside $6	Outperform Upgraded	2 Apr 2025
Piper Sandler Biren Amin 22% 1-year accuracy 6 / 27 met price target	545%upside $12	Overweight Initiated	19 Feb 2025
Jefferies Maury Raycroft 13% 1-year accuracy 1 / 8 met price target	330%upside $8	Buy Maintained	10 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about CMPX published over the past 30 days

Neutral

GlobeNewsWire

2 days ago

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in these models.

$Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting$